Publicacions Institut d’Oncologia de la Catalunya Sud (IOCS)

Any 2025

Articles:

  • Fernández-Castillejo S, Badia J, de la Cruz-Merino L, Martín Garcia-Sáncho A, Carnicero-González F, Palazón-Carrión N, Ríos-Herranz E, de la Cruz-Vicente F, Rueda-Domínguez A, Martínez-Banaclocha N, Gómez-Codina J, Labrador J, Martínez-Madueño F, Amigó N, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Sánchez-Beato M, Provencio-Pulla M, Guirado-Risueño M, Nogales E, Sánchez-Margalet V, Jiménez-Cortegana C, Rodríguez-García G, Cumeras R, Gumà J; Spanish Lymphoma Oncology Group (GOTEL). Ketone Bodies Are Potential Prognostic Biomarkers in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results from the R2-GDP-GOTEL Trial. Cancers (Basel). 2025 Feb 5;17(3):532. doi: 10.3390/cancers17030532. PMID: 39941898; PMCID: PMC11817199. IF 4.401 Q1
  • Llambrich M, van der Kloet FM, Sementé L, Rodrigues A, Samanipour S, Stefanuto PH, Westerhuis JA, Cumeras R, Brezmes J. GcDUO: an open-source software for GC × GC-MS data analysis. Brief Bioinform. 2025 Mar 4;26(2):bbaf080. doi: 10.1093/bib/bbaf080. PMID: 40037642; PMCID: PMC11879434. IF 7,966 Q1
  • Miranda Pallarés MJ, Álvaro Naranjo T, Vidal Rodriguez A, Martínez Madueño F. Unusual Long-Term Survival in an Adult Patient With Langerhans Cell Histiocytosis and Central Nervous System Involvement: A Case Report. Case Rep Hematol. 2025 May 16;2025:6031427. doi: 10.1155/crh/6031427. PMID: 40416903; PMCID: PMC12101904. IF 0,7 Q4
  • Gumà J, Palazón-Carrión N, Rueda-Domínguez A, Sequero S, Calvo V, García-Arroyo R, Gómez-Codina J, Llanos M, Martínez-Banaclocha N, Provencio M. SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025). Clin Transl Oncol. 2025 Dec;27(12):4381-4392. doi: 10.1007/s12094-025-04080-z. Epub 2025 Oct 23. PMID: 41129029; PMCID: PMC12630300. IF 3,043 Q2
  • Hontecillas-Prieto L, García-Domínguez DJ, Jiménez-Cortegana C, Nogales-Fernández E, Palazón-Carrión N, García-Sancho AM, Ríos-Herranz E, Gumà-Padrò J, Provencio-Pulla M, Rueda-Domínguez A, de la Cruz-Merino L, Sánchez-Margalet V. Obesity and overweight in R/R DLBCL patients is associated with a better response to treatment of R2-GDP-GOTEL trial. Potential role of NK CD8 + cells and vitamin D. Cancer Metab. 2025 Mar 4;13(1):12. doi: 10.1186/s40170-025-00381-7. PMID: 40038834; PMCID: PMC11881355. IF 5.4 Q1
  • Varela M, Teixidó C, Álvarez-Fernández C, Arasanz H, Peralta S, Lázaro M, Calvo V, Álvarez R, Baena J, Valdivia J, Arriola E, Bernabé R, Isla D, Camacho C, Massutí B, Blasco A, García T, Cobo M, Campayo M, Hijazo-Pechero S, Callejo Á, Domínguez M, Nadal E. Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study. Transl Lung Cancer Res. 2025 Apr 30;14(4):1254-1265. doi: 10.21037/tlcr-2024-1146. Epub 2025 Apr 21. PMID: 40386732; PMCID: PMC12082214. IF 3,315 Q1
  • Gallego A, Madariaga A, Estévez-García P, Albertí F, Carbó A, Palacio I, Churruca C, Gálvez F, Ortega ME, Murata P, Manzano A, Masvidal M, Martín-Lorente C, Hernando B, Lozano I, Cueva JF, García-Illescas D, Gost E, Mendiola M, Redondo A. An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study). Int J Gynecol Cancer. 2025 Jul;35(7):101903. doi: 10.1016/j.ijgc.2025.101903. Epub 2025 Apr 26. PMID: 40382973. IF 4.1 Q2
  • Vidal M, Falato C, Pascual T, Sanchez-Bayona R, Muñoz-Mateu M, Cebrecos I, Gonzalez-Farré X, Cortadellas T, Margelí Vila M, Luna MA, Siso C, Amillano K, Galván P, Bergamino MA, Ferrero-Cafiero JM, Salvador F, Espinosa Guerrero A, Pare L, Sanfeliu E, Prat A, Bellet M. Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial. Clin Cancer Res. 2025 Apr 1;31(7):1223-1232. doi: 10.1158/1078-0432.CCR-24-2460. PMID: 39820652; PMCID: PMC11959270. IF 8,534 Q1
  • Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, Untch M, Bonnefoi H, Kim SB, Seiler S, Bear HD, Witkiewicz AK, Im SA, DeMichele A, Pehl A, Van't Veer L, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff CC, Kelly CM, Reimer T, Felder B, Melé Olivé M, Knudsen ES, Turner N, Rojo F, Schmitt WD, Fasching PA, Teply-Szymanski J, Zhang Z, Toi M, Rugo HS, Gnant M, Makris A, Holtschmidt J, Nekljudova V, Loibl S. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping. Cancer Cell. 2025 Feb 10;43(2):232-247.e4. doi: 10.1016/j.ccell.2025.01.002. PMID: 39933898. IF 24,691 Q1
  • Camps J, Jiménez-Franco A, García-Pablo R, Joven J, Arenas M. Artificial intelligence-driven integration of multi-omics and radiomics: A new hope for precision cancer diagnosis and prognosis. Biochim Biophys Acta Mol Basis Dis. 2025 Aug;1871(6):167841. doi: 10.1016/j.bbadis.2025.167841. Epub 2025 Apr 9. PMID: 40216368. IF 4,728 Q1
  • Arenas M, Bölükbaşı Y, Boersma LJ, Offersen B, Kouloulias V, Palumbo I, Trigo L, Lozza L, Marazzi F, Trovo M, Rivera S, Kaidar-Person O, Coles C, Meattini I, Valentini V, Aristei C, Poortmans P; Assisi Think Tank Meeting (ATTM) 2024 members. The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy. Breast. 2025 Apr;80:103881. doi: 10.1016/j.breast.2025.103881. Epub 2025 Jan 20. PMID: 39854807; PMCID: PMC11804728. IF 7,871 Q1
  • Gomis Sellés E, Mingarro de León M, Montero Á, Arenas M. Burnout levels among radiation oncology residents in Spain: a cross-sectional survey. Clin Transl Oncol. 2025 Aug;27(8):3543-3549. doi: 10.1007/s12094-025-03862-9. Epub 2025 Feb 12. PMID: 39937361. IF 2.8 Q2
  • Rubió-Casadevall J, Trallero J, Calvo C, Puigdemont M, Carulla M, Sanvisens A, Ameijide A, Vidal A, Pla C, Marruecos J, Marcos-Gragera R, Galceran J. A population-based study of incidence trends of head and neck epithelial cancers in northeastern Spain, 1994-2018. Clin Transl Oncol. 2025 Aug;27(8):3410-3420. doi: 10.1007/s12094-025-03855-8. Epub 2025 Feb 19. PMID: 39971848; PMCID: PMC12259777. IF 2.8 Q2
  • Montero A, Arenas M, Aistei C. SIRARIS: Survey of internal mammary radiotherapy among radiation oncologists from Italy & Spain. Clin Transl Oncol. 2025 Apr;27(4):1839-1844. doi: 10.1007/s12094-024-03693-0. Epub 2024 Sep 1. PMID: 39218812. IF 2.8 Q2
  • Loibl S, Martin M, Bonnefoi H, Untch M, Kim SB, Bear HD, García-Sáenz JA, Melé Olivé M, Mc Carthy N, Gelmon K, Kelly CM, Im SA, Reimer T, Martinez-Janez M, Zhang Z, Toi M, Provencher L, Rugo HS, Gnant M, Makris A, Antón Torres A, Hirmas N, Holtschmidt J, Nekljudova V, Marmé F. Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy. Ann Oncol. 2025 Jul;36(7):832-837. doi: 10.1016/j.annonc.2025.03.010. Epub 2025 Mar 24. PMID: 40139460. IF 22,614 Q1
  • Galceran J, Ameijide A, Cañete A, Peris-Bonet R, López de Munain A, Aizpurúa A, de la Cruz M, Sanvisens A, Sánchez MJ, Palacios I, Franch P, Sánchez A, Guevara M, Carulla M, Gutiérrez P, Sáez I, Rodríguez M, Alemán A, Sabater C; Spanish Network of Cancer Registries (REDECAN). Trends in the incidence of brain cancer and the use of mobile phones: analysis of the Spanish Network of Cancer Registries (REDECAN). Clin Transl Oncol. 2025 Nov;27(11):4221-4231. doi: 10.1007/s12094-025-03932-y. Epub 2025 May 14. PMID: 40366608; PMCID: PMC12559055.IF 2.8 Q2
  • Trama A, Bernasconi A, Cañete A, Carulla M, Daubisse-Marliac L, Rossi S, De Angelis R, Sanvisens A, Katalinic A, Paapsi K, Went P, Mousavi M, Blum M, Eberle A, Lamy S, Capocaccia R, Didonè F, Botta L; EUROCARE-6 WG. Incidence and survival of rare adult solid cancers in Europe (EUROCARE-6): A population-based study. Eur J Cancer. 2025 Jan;214:115147. doi: 10.1016/j.ejca.2024.115147. Epub 2024 Nov 27. PMID: 39647345. IF 4,381 Q1
  • Botta L, Didonè F, Lopez-Cortes A, Nieto AC, Desandes E, Hjalgrim LL, Jakab Z, Stiller CA, Zeller B, Gatta G, Pritchard-Jones K; BENCHISTA Project Working Group (Marià Carulla). International benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study. Lancet Child Adolesc Health. 2025 Feb;9(2):89-99. doi: 10.1016/S2352-4642(24)00302-X. Erratum in: Lancet Child Adolesc Health. 2025 Mar;9(3):e9. doi: 10.1016/S2352-4642(25)00037-9. Erratum in: Lancet Child Adolesc Health. 2025 May;9(5):e13. doi: 10.1016/S2352-4642(25)00096-3. PMID: 39855760. IF 5.111 Q1
  • Henríquez I, Malave B, López Campos F, Hidalgo EC, Muelas R, Ferrer C, Muñoz-Rodriguez J, Villamón AM, Pascual MC, Badia J, Fuertes J, Hinojosa-Salas P. PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC). Clin Transl Oncol. 2025 Feb;27(2):706-715. doi: 10.1007/s12094-024-03625-y. Epub 2024 Jul 29. PMID: 39073734. IF 2.8 Q2
  • Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, Gavila J, Schmid P, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Di Cosimo S, Anton A, Cottu P, Shimizu E, Fernandez M, Sampayo-Cordero M, Cortés J; PARSIFAL-LONG Steering Committee and Trial Investigators. Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. ESMO Open. 2025 Jul;10(7):105309. doi: 10.1016/j.esmoop.2025.105309. Epub 2025 Jun 17. PMID: 40532361; PMCID: PMC12212146. IF 6.3 Q1
  • Crespo I, Goni-Fuste B, Monforte-Royo C, Garcia-Salanova A, Rodríguez-Prat A, Alonso-Babarro A, Alvaro M, Bavestrello P, Belar A, Bottaro D, Candelmi D, Casas E, Costas-Muñoz E, Sequeiros CC, de Iriarte N, De Santiago A, Garrillo J, González-Barboteo J, Ariztia MJ, Vicuña MN, Nitola-Mendoza L, Noguera-Sánchez P, Rocafort J, Rodríguez D, Sala C, Serna J, Torremorell D, Balaguer A, Julià-Torras J. Implementation of a clinical interview guide to Multidimensional needs assessment in Palliative care (MAP): A multicenter mixed-methods feasibility study. PLoS One. 2025 Jul 31;20(7):e0329354. doi: 10.1371/journal.pone.0329354. PMID: 40743053; PMCID: PMC12312908. IF 2.82 Q1
  • Parejo Arrondo MT, Griso Jurado B, Bayona Escat L, Ortiz-Miluy G, Grau Farrús IC, Gumà J. Performance and safety of Femorally Inserted Central Catheters in oncological patients: A cases series analysis. J Vasc Access. 2025 Oct 7:11297298251375510. doi: 10.1177/11297298251375510. Epub ahead of print. PMID: 41058159. IF 2,154 Q2
  • Seguí E, Brasó-Maristany F, Pascual T, Sanfeliu E, Victoria I, Saura C, Hierro C, López-González A, Izarzugaza Y, Ciruelos E, Gavilá J, Racca F, Cejalvo JM, Amillano K, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Conte B, Walbaum B, Indacochea A, Castillo O, Blasco P, Pardo F, Aguirre Á, Sirenko V, González X, Galván P, Vivancos A, Ferrero-Cafiero JM, Mulero-Sánchez A, Salvador F, Villacampa G, Mesía R, Cervantes A, Prat A, Tabernero J. Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial. ESMO Open. 2025 Oct;10(10):105838. doi: 10.1016/j.esmoop.2025.105838. Epub 2025 Sep 30. PMID: 41033278; PMCID: PMC12514499. IF 6,399 Q1
  • Duque-Santana V, Gómez-Aparicio MA, Ocanto A, Selles EG, Gaztañaga M, Willisch P, Pijoan XM, Blanco-Villar ML, Henriquez I, Lara PC, Ribeiro I, Ramirez AG, Valcárcel ML, de Manzanos IVF, Echagüen SP, Martínez PA, Barragán VV, Millán CV, Vacas AI, Ots PMS, Glaría Enríquez LA, Luis AM, Niño LM, Del Castillo Acuña R, Del Portillo EG, Ferrer F, Gómez-Iturriaga A, Conde Moreno AJ, Del Cerro Peñalver E, Couñago F, López-Campos F; URONCOR investigators. Management of high-risk prostate cancer in Spain: results from a national patterns of care survey. Clin Transl Oncol. 2025 Oct 29. doi: 10.1007/s12094-025-04078-7. Epub ahead of print. PMID: 41160367. IF 2.8 Q2
  • González San Segundo C, López-Campos F, Gómez Iturriaga A, Santos M, Ocanto A, Montezuma L, Boladeras-Inglada AM, Glaria L, Guardado S, Rodríguez A, Henríquez I, Olivera J, Duque-Santana V, Garre J, Moreno S, Valero J, Conde AJ, Doval A, Sancho G, Martin Nieto P, Castaño Cantos A, García N, Fernández Alonso S, García García R, Díaz Gavela A, Buchser D, Maldonado X, Mases J, Hernando Requejo O, Sanmamed N, Martínez Salamanca JI, Couñago F. Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial. Actas Urol Esp (Engl Ed). 2025 Sep;49(7):501823. English, Spanish. doi: 10.1016/j.acuroe.2025.501823. Epub 2025 Jul 31. PMID: 40752730. IF 1.14 Q3
  • Hoogendijk R, Capocaccia R, van der Lugt J, Kranendonk MEG, Hoving EW, Wesseling P, Visser O, van Vuurden DG, Gatta G, Karim-Kos HE; EUROCARE working group (Jaume Galceran, Marià Carulla). Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study. Lancet Oncol. 2025 Aug;26(8):1091-1099. doi: 10.1016/S1470-2045(25)00297-9. PMID: 40744027. IF 9.61 Q1
  • Trallero J, Romaguera A, Ameijide A, Cañete A, Pardo E, Alfonso P, Jeghalef-El-Karoui N, De-La-Cruz M, Onaindia-Agundez A, Sanvisens A, Redondo-Sánchez D, Perucha J, Ruiz-Armengol P, Chirlaque MD, Guevara M, Gutiérrez P, Pla C, Merino-Perera S, Garrido-Martín M, Vizcaino-Batlles A, Lopez-de-Munain A, Marcos-Gragera R; REDECAN. Survival trends and cure rates of hematological neoplasms in the Spanish pediatric population. Eur J Epidemiol. 2026 Jan;41(1):77-88. doi: 10.1007/s10654-025-01306-w. Epub 2025 Sep 24. PMID: 40991150. IF 5.68 Q1
  • Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Dal Maso L, Lepage C, Molinié F, Bouvier AM, Marcos-Gragera R, Vener C, Guevara M, Murray D, Ragusa R, Gatta G, Jooste V; EUROCARE-6 WG. The impact of cancer survivors' extra risk of noncancer mortality on net survival estimation. Am J Epidemiol. 2025 Nov 4;194(11):3316-3324. doi: 10.1093/aje/kwaf148. PMID: 40826891; PMCID: PMC12634115. IF 4,061 Q1
  • Gatta G, Luttmann S, Trama A, Rossi S, Galceran J, Innos K, Guevara M, Licitra L, Bennet D, Redondo-Sánchez D, Capocaccia R; EUROCARE WG. Epithelial head and neck cancer survival in Europe: Geographical variation, time trends and long term survival. Eur J Cancer. 2025 Oct 16;229:115692. doi: 10.1016/j.ejca.2025.115692. Epub 2025 Aug 19. Erratum in: Eur J Cancer. 2026 Jan;232:116147. doi: 10.1016/j.ejca.2025.116147. PMID: 40945302. 4,381 Q1
  • Suárez C, Reig Torras Ò, Morales Barrera R, Rodríguez Sánchez Á, Anguera Palacios G, Manshino AMB, Fernández Núñez N, Méndez Vidal MJ, García Carbonero I, Fernández Calvo O, Gironés Sarrió R, Crespo Herrero G, Afonso Afonso J, Juan Fita MJ, Gumà Padró J, Lázaro Quintela M, Rodriguez-Vida A, Hernández Pérez C, Medina Colmenero A, Collado Martín R, Garcías de España C, Molins Palau C, Martínez Ortega E, Gallardo E; SPRWEC Study investigators. Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study. Clin Genitourin Cancer. 2025 Oct;23(5):102402. doi: 10.1016/j.clgc.2025.102402. Epub 2025 Jul 23. PMID: 40830022. IF 2,637 Q2
  • Trujillo-Santos J, García-Escobar I, Salgado M, Araújo A, Martínez-de-Castro E, Molina R, Castellón-Rubio VE, Domènech P, Gallardo E, Colomé E, Torres F, Benítez-Montañez JC, Porta R, Lobo-de-Mena M, Malheiro M, Font C, Brozos-Vázquez E, Garicano F, Sapena V, Costa AL, Albuquerque AC, Cerezuela P; CARTAGO Study Group (Clara Lucia, Maria Masvidal). Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study. Oncologist. 2025 Aug 4;30(8):oyae334. doi: 10.1093/oncolo/oyae334. PMID: 39673414; PMCID: PMC12395237. IF 4,146 Q1
  • Borrego MR, López-Bravo DP, Vila MM, Pérez-García JM, Fernández M, Tormo SB, García-Saenz JÁ, Lema L, Garau I, Cortez P, Torres AA, Conejo EA, Calvo I, Ferrer N, Blancas I, Amillano K, Santasusagna S, Benderra MA, Alcalá-López D, Antonarelli G, Sampayo-Cordero M, Llombart-Cussac A, Cortés J. Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study. Eur J Cancer. 2026 Jan 17;233:116161. doi: 10.1016/j.ejca.2025.116161. Epub 2025 Dec 4. PMID: 41371050. IF 4,381 Q1
  • Goni-Fuste B, Crespo I, García-Salanova A, Monforte-Royo C, Rodríguez-Prat A, Alonso A, Belar A, Bottaro D, Candelmi D, Cimerman J, Costas E, de Iriarte N, Garrillo J, González-Barboteo J, Jimeno M, Nabal Vicuña M, Noguera-Sánchez P, Rocafort J, Rodríguez D, Sala C, Serna J, Balaguer A, Julià-Torras J. Development of a Revised Clinical Guide to Multidimensional Needs Assessment in Palliative Care: MAP. J Pain Symptom Manage. 2025 Dec 24:S0885-3924(25)01019-X. doi: 10.1016/j.jpainsymman.2025.12.014. Epub ahead of print. PMID: 41453588. IF 3.5 Q1
  • Masini S, Antoñanzas Basa M, Calles A, Cabellos RA, De Elejoste Echebarria I, Traseira Puchol C, Martinez Kareaga M, Cabezon-Gutierrez L, Escoin Perez MC, Lage Y, Garcia Lorenzo E, Navarro F, Sereno M, Falagán Martínez S, García-Benito C, Masfarre Pinto L, Avila Andrade C, Sequero S, Mosquera Martinez J, López-Martín A, Azkárate Martínez A, Martín-Soberón MC, Lucia-Gozalvez C, Rubio J, Tallafigo L, Garrido A, Peressini M, Torres-Jimenez J, Zurera M, Bote H, Ponce S, Paz-Ares L, Zugazagoitia J, Baena J. Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study). Cancers (Basel). 2025 Nov 13;17(22):3643. doi: 10.3390/cancers17223643. PMID: 41301009; PMCID: PMC12651785. IF 4.4 Q2
  • Isla D, Zugazagoitia J, Arriola E, García-Campelo R, Martí Blanco C, Diz-Taín MP, López-Brea M, Moreno-Vega AL, León-Mateos L, Oramás J, Gutiérrez-Calderón V, Majem M, Sánchez-Hernández A, Aguado C, Alvarez-Cabellos R, Massutí B, Moreno A, Fírvida-Pérez JL, Valdivia J, González-Cordero M, Zafra-Poves M, Dómine M, Garcia-Navalon FJ, Villanueva N, Provencio M, Juan-Vidal O, Rivas-Corredor C, Olmedo García ME, Palmero R, López-Castro R, Carcereny E, Lechuga JL, Domínguez M, Callejo Á, Paz-Ares L. Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial. Lung Cancer. 2025 Nov;209:108763. doi: 10.1016/j.lungcan.2025.108763. Epub 2025 Sep 24. PMID: 41033130. IF. 4.4 Q2
  • Hospitals ICO, l'Hospital Universitari Sant Joan de Reus, l'Hospital Universitari Arnau de Vilanova, l'Hospital Universitari Vall d'Hebron, l'Hospital de la Mar, l'Hospital Universitari Parc Taulí i l'Hospital de la Santa Creu i Sant Pau. ICO-ICS Praxi: Tractament mèdic- quirúrgic i amb irradiació dels tumors cutanis. Gencat. Setembre 2025

Any 2024

Articles:

  • Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart- Cussac A; PHERGain Trial Investigators. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response- adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054- 0. Impact Factor: 54.433, Quartile: Q1.
     

  • Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Calvo Martínez L, Ribelles N, Fernandez-Abad M, Albacar C, Colleoni M, Garrigos L, Atienza de Frutos M, Dalenc F, Prat A, Marmé F, Schmid P, Kerrou K, Braga S, Gener P, Sampayo-Cordero M, Cortés J, Pérez-García JM, Llombart-Cussac A. Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial. J Nucl Med. 2024 May 1;65(5):708-713. Impact Factor:: 10.057, Q1.
     
  • Llambrich M, Satorra P, Correig E, Gumà J, Brezmes J, Tebé C, Cumeras R. Easy-Amanida: An R Shiny application for the meta-analysis of aggregate results in clinical metabolomics using Amanida and Webchem. Res Synth Methods. 2024 Mar 13:e1713. doi: 10.1002/jrsm.1713. Epub ahead of print. PMID: 38480474. Impact Factor: 7.216, Quartile: Q1.
     
  • Martínez-Banaclocha N, Martínez-Madueño F, Caballé B, Badia J, Blanes M, Bujanda DA, Calvo V, Gómez Codina J, Blanco CQ, Espinosa P, Lavernia J, Arroyo FRG, Risueño MG, Llorca C, Cumeras R, Pulla MP, Gumà J. A Descriptive Study of 103 Primary Cutaneous B- Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL). Cancers (Basel). 2024 Mar 3;16(5):1034. doi: 10.3390/cancers16051034. PMID: 38473391; PMCID: PMC10931196. Impact Factor: 6.6, Quartile: Q1.
     
  • Jiménez-Franco A, Castañé H, Martínez-Navidad C, Placed-Gallego C, Hernández-Aguilera A, Fernández-Arroyo S, Samarra I, Canela-Capdevila M, Arenas M, Zorzano A, Hernández- Alvarez MI, Castillo DD, Paris M, Menendez JA, Camps J, Joven J. Metabolic adaptations in severe obesity: Insights from circulating oxylipins before and after weight loss. Clin Nutr. 2024 Jan;43(1):246-258. doi: 10.1016/j.clnu.2023.12.002. Epub 2023 Dec 6. PMID: 38101315. Impact Factor: 6.1, Quartile: Q1.
     
  • Peressini M, Garcia-Campelo R, Massuti B, Marti C, Cobo M, Gutiérrez V, Dómine M, Fuentes J, Majem M, de Castro J, Cordoba JF, Diz MP, Isla D, Esteban E, Carcereny E, Vila L, Moreno- Vega A, Ros S, Moreno A, Garcia FJ, Huidobro G, Aguado C, Cebey-Lopez V, Valdivia J, Palmero R, Lianes P, Lopez-Brea M, Vidal OJ, Provencio M, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V, Ponce-Aix S, Nuñez-Buiza A, Ucero Á, Hernandez S, Lopez- Rios F, Conde E, Paz-Ares L, Zugazagoitia J. Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer. Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0104. Epub ahead of print. PMID: 38630755. Impact Factor: 12.01, Quartile: Q1.
     
  • Torres-Esquius S, Llop-Guevara A, Gutiérrez-Enríquez S, Romey M, Teulé À, Llort G, Herrero A, Sánchez-Henarejos P, Vallmajó A, González-Santiago S, Chirivella I, Cano JM, Graña B, Simonetti S, Díaz de Corcuera I, Ramon Y Cajal T, Sanz J, Serrano S, Otero A, Churruca C, Sánchez-Heras AB, Servitja S, Guillén-Ponce C, Brunet J, Denkert C, Serra V, Balmaña J. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Netw Open. 2024 Apr 1;7(4):e247811. doi: 10.1001/jamanetworkopen.2024.7811. PMID: 38648056; PMCID: PMC11036141. Impact Factor: 22.5, Quartile: Q1.
     
  • José M. Moreno-Cabrera, Lidia Feliubadaló, Marta Pineda, Patricia Prada-Dacasa, Mireia Ramos-Muntada, Jesús del Valle, Joan Brunet, Bernat Gel, María Currás-Freixes, Bruna Calsina, Milton E. Salazar-Hidalgo, Marta Rodríguez-Balada, Bàrbara Roig, Sara Fernández- Castillejo, Mercedes Durán Domínguez, Mónica Arranz Ledo, Mar Infante Sanz, Adela Castillejo, Estela Dámaso, José L. Soto, Montserrat de Miguel, Beatriz Hidalgo Calero, José M. Sánchez-Zapardiel, Teresa Ramon y Cajal, Adriana Lasa, Alexandra Gisbert-Beamud, Anael López-Novo, Clara Ruiz-Ponte, Miriam Potrony, María I. Álvarez-Mora, Ana Osorio, Isabel Lorda-Sánchez, Mercedes Robledo, Alberto Cascón, Anna Ruiz, Nino Spataro, Imma Hernan, Emma Borràs, Alejandro Moles-Fernández, Julie Earl, Juan Cadiñanos, Ana B. Sánchez-Heras, Anna Bigas. The SpadaHC Consortium, Gabriel Capellá, Conxi Lázaro. SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population.22 Database (Oxford). 2024 Jul 4;2024:baae055. PMID: 38965703. Impact Factor: 5.235, Quartile: Q2.
     
  • Anna Pedret, Judit Companys, Lorena Calderón-Pérez, Elisabet Llauradó, Laura Pla-Pagà, Patricia Salamanca, Berner-Andree Sandoval-Ramírez, Úrsula Catalán, Sara Fernández-Castillejo, Silvia Yuste, Alba Macià, Laia Gutiérrez-Tordera, Mónica Bulló, Jordi Camps, Núria Canela, Rosa Maria Valls, Laura Rubió-Piqué, Maria José Motilva, Rosa Solà. A red-fleshed apple rich in anthocyanins improves endothelial function, reduces inflammation, and modulates the immune system in hypercholesterolemic subjects: the AppleCOR study. Food Funct. 2024 Jun 4;15(11):5825-5841. PMID: 38751340.Impact Factor: 4.5, Quartile: Q2.
     
  • Llambrich M, Ramírez N, Cumeras R, Brezmes J. SPME arrow-based extraction for enhanced targeted and untargeted urinary volatilomics. Anal Chim Acta. 2024;1245:343261. doi:10.1016/j.aca.2024.343261.Impact Factor: 7.216, Quartile: Q1.
     
  • Martínez-Banaclocha, N., Martínez-Madueño, F., Caballé, B., Badia, J., Blanes, M., Bujanda, D. A., Calvo, V., Gómez Codina, J., Blanco, C. Q., Espinosa, P., Lavernia, J., Arroyo, F. R. G., Risueño, M. G., Llorca, C., Cumeras, R., Pulla, M. P., & Gumà, J. A descriptive study of 103 primary cutaneous B-cell lymphomas: clinical and pathological characteristics and treatment from the Spanish Lymphoma Oncology Group (GOTEL). Cancers. 2024;16(5):1034. doi:10.3390/cancers16051034.Impact Factor: 6.6, Quartile: Q1.
     
  • Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). J Neurooncol. 2024;168(2):299-306. doi:10.1007/s11060-024-04668-5. Impact Factor: 4.692, Quartile: Q2
     
  • Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S,23 Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma. J Neurooncol. 2024;166(2):407-415. doi:10.1007/s11060-023-04513-1. Impact Factor: 4.692, Quartile: Q2.
     
  • Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores- Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar- Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio- Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda- Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L.CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B-cell lymphoma. Front Immunol. 2024;15:1293931. doi:10.3389/fimmu.2024.1293931.Impact Factor: 5.749, Quartile: Q1.
     
  • Masvidal Hernandez M, Cros Costa S, Salvador Coloma C, Quilez Cutillas A, Barretina- Ginesta MP, Cotes Sanchís A. First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature. Clin Transl Oncol. 2024. doi:10.1007/s12094-024-03609-y. Impact Factor: 3.492, Quartile: Q2.
     
  • GEINO Study Group. Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study. Ann Oncol. 2024;35(5):789-798. doi:10.1016/j.annonc.2024.03.001. Impact Factor: 32.976, Quartile: Q1.
     
  • Maldonado V, Masvidal M, Morente-Laguna V, Cimerman J, Martinez-Soriano S. Atypical Presentation of an Ovarian Yolk Sac Tumor in an 80-Year-Old Woman: A Case Report and Review of the Literature. Case Rep Oncol. 2024;17(1):1342-1350. doi:10.1159/000542244. Impact factor: 0.7, Quartile:Q4
     
  • Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz-Borrego M, Gavilá J, Aguirre E, Schmid P, Marmé F, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez de Dueñas E, Amillano K, Shimizu E, Sampayo-Cordero M, Cortés J, Llombart-Cussac A. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor- positive/HER2-negative advanced breast cancer. Breast. 2024 Aug;76:103761. doi:10.1016/j.breast.2024.103761. Epub 2024 Jun 11. PMID: 38880077; PMCID: PMC11228587. Impact Factor: 5.421, Quartile: Q124
     
  • Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart- Cussac A; PHERGain Trial Investigators. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response- adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054-0. Epub 2024 Apr 3. PMID: 38582092. Impact Factor: 14.325 , Quartile: Q1
     
  • De Angelis R, Demuru E, Baili P, Troussard X, Katalinic A, Chirlaque MD, Innos K, Santaquilani M, Blum M, Ventura L, Paapsi K, Galasso R, Guevara M, Randi G, Bettio M, Botta L, Guzzinati S, Dal Maso L, Rossi S, EUROCARE-6 Working Group. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. Lancet Oncol. 2024 Mar;25(3):293-307. doi: 10.1016/S1470-2045(23)00646-0. Impact factor: 41.6, Quartile: Q1
     
  • Trama A, Botta L, Stiller C, Visser O, Cañete-Nieto A, Spycher B, Bielska-Lasota M, Katalinic A, Vener C, Innos L, Marcos-Gragera R, Paapsi K, Guevara M, Demuru E, Mohsen Mousavi S, Blum M, Eberle A, Ferrari A, Bernasconi A, Lasalvia P, EUROCARE-6 Working Group. Survival of European adolescents and young adults diagnosed with cancer in 2010-2014. Eur J Cancer. 2024 May:202:113558. doi: 10.1016/j.ejca.2024.113558. Impact factor: 7.6, Quartile: Q1
     
  • Virgili G, Capocaccia R, Botta L, Bennett D, Hadjistilianou T, Innos K, Karim-Kos H, Kuehni C, Kuhnel U, Mazzini C, Cañete A, Paapsi K, Parravano M, Ronckers C, Rossi S, Stiller C, Vicini G, Visser O, Gatta G, EUROCARE-6 Working Group. Survival and Health Care Burden of Children With Retinoblastoma in Europe. JAMA Ophthalmol. 2024 Oct 10;142(11):1062-1070. doi: 10.1001/jamaophthalmol.2024.4140. Impact factor: 8, Quartile: Q1
     
  • Sant M, Vener C, Lillini R, Rossi S, Bonfarnuzzo S, Marcos-Gragera R, Maynadié M, Innos K, Paapsi K, Visser O, Bernasconi A, Demuru E, Di Benedetto C, Mohsen S, Blum M, Went P, Serraino D, Bennett D, Sánchez MJ, De Angelis R, EUROCARE-6 Working Group. Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study. Lancet Oncol. 2024 Jun;25(6):731-743. doi:10.1016/S1470-2045(24)00141-4.. Impact factor: 41.6, Quartile: Q1
     
  • Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Dal Maso L, Lepage C, Molinié F, Bouvier A, Marcos-Gragera R, Vener C, Guevara M, Murray D, Ragusa R, Gatta G, Jooste V, EUROCARE-6 Working Group. Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on Head & Neck, Colorectal, and Breast cancers. Eur J Cancer. 2024 Sep:208:114187. doi: 10.1016/j.ejca.2024.114187. Impact factor: 7.6, Quartile: Q1
     
  • Nguyen NP, Mohammadianpanah M, SunMyint A, Page BR, Vinh-Hung V, Gorobets O, Arenas M, Mazibuko T, Giap H, Vasileiou M, Dutheil F, Tuscano C, Karlsson UL, Dahbi Z, Natoli E, Li25 E, Kim L, Oboite J, Oboite E, Bose S, Vuong T. Immunotherapy and radiotherapy for older patients with locally advanced rectal cancer unfit for surgery or decline surgery: a practical proposal by the International Geriatric Radiotherapy Group. Front Oncol. 2024 Feb 22;14:1325610. doi: 10.3389/fonc.2024.1325610. Impact Factor: 3.5, Quartile: Q2.
     
  • NP Nguyen; ME Chirila; BR Page; V Vinh-Hung; O Gorobets; M Mohammadianpanah; H Giap; M Arenas; M Bonet; PC Lara; L Kim; F Dutheil; D Lehrman; L Zegarra Montes; G Tlili; Z Dahbi; G Loganadane; S Calleja Blanco; S Bose; E Natoli; E Li; A Mallun; AG Morganti. Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group. Frontiers in Oncology. 2024. DOI: 10.3389/fonc.2024.1391464. Impact Factor: 3.5, Quartile: Q2.
     
  • Castro-Larefors S, Marti-Laosa MM, Lopez-Honrubia V, Rey-Lopez I, Ruiz-Herrero B, Murria- Perez Y, Andres I, Jimenez-Garcia IE, Berenguer R, Aguayo-Martos M, Sánchez-Prieto R, Rovirosa A, Jimenez-Jimenez E, Arenas M, Sabater S. Longer time to testosterone recovery impacts favorably on outcomes for prostate cancer following androgen deprivation and radiotherapy. Strahlenther Onkol. 2024 Feb 28. doi: 10.1007/s00066-024-02208-8. Epub ahead of print. PMID: 38416163. Impact Factor: 3.692, Quartile: Q2.
     
  • Sola AB, Otón LF, Guedea F, Arenas M. A nationwide survey of the current status of radiation oncology teaching in Spanish medical schools. Rep Pract Oncol Radiother. 2024 Feb 16;28(6):794-800. doi: 10.5603/rpor.98741. PMID: 38515816; PMCID: PMC10954273. Impact Factor: 3.492, Quartile: Q2
     
  • M Murcia-Mejía; M Canela-Capdevila; R García-Pablo; A Jiménez-Franco; JM Jiménez Aguilar; J Badia; R Benavides-Villarreal; JC Acosta; M Arguis; AI Onoiu; H Castañé; J Camps; M Arenas; J Joven. Combining Metabolomics and Machine Learning to Identify Diagnostic and Prognostic Biomarkers in Patients with Non-Small Cell Lung Cancer Pre- and Post-Radiation Therapy. Biomolecules. 1, Springer, 2024. DOI: 10.3390/biom14080898. Impact Factor: 4,8, Quartile: Q1
     
  • M Arenas; M Fargas-Saladié; M Moreno-Solé; L Moyano-Femenia; A Jiménez-Franco; M Canela-Capdevila; H Castañé; C Martínez-Navidad; J Camps; J Joven. Metabolomics and26 triple-negative breast cancer: A systematic review. Heliyon. 10 - 1, Springer, 2024. DOI: 10.1016/j.clnu.2023.12.002. Impact Factor: 3.4, Quartile: Q1
     
  • A Montero; Meritxell Arenas; C Aristei. SIRARIS: Survey of internal mammary radiotherapy among radiation oncologists from Italy & Spain. Clin Transl Oncol.Springer, 2024. Impact Factor: 3.405, Quartile: Q2
     
  • A Jiménez-Franco; H Castañé; C Martínez-Navidad; C Placed-Gallego; A Hernandez-Aguilera; S Fernandez-Arroyo; I Samarra; M Canela-Capdevila; M Arenas; A Zorzano; MI Hernandez- Alvarez; D Del Castillo; M Paris; JA Menendez; J Camps; J Joven. Metabolic adaptations in severe obesity: Insights from circulating oxylipins before and after weight loss. Clin Nutr. 43 - 1, pp. 246 - 258. Springer, 2024. Impact Factor: 6.6, Quartile: Q1
     
  • Incidence and survival of rare adult solid cancers in Europe (EUROCARE-6): A population-based study. Trama A, Bernasconi A, Cañete A, Carulla M, Daubisse-Marliac L, Rossi S, De Angelis R, Sanvisens A, Katalinic A, Paapsi K, Went P, Mousavi M, Blum M, Eberle A, Lamy S, Capocaccia R, Didonè F, Botta L. Eur J Cancer. 2025 Jan:214:115147. doi: 10.1016/j.ejca.2024.115147. Epub 2024 Nov 27. Impact factor: 7.6
     
  • Cancer Incidence in Five Continents, Vol XII. Bray F, Colombet M, Aitken JF, Bardot A, Eser S, Galceran J, Hagenimana M, Matsuda T, Mery L, Piñeros M, Soerjomataram I, de Vries E, Wiggins C, Won Y-J, Znaor A, Ferlay J, editors (2024). Lyon: International Agency for Research on Cancer.